The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Multiple Sclerosis Therapeutics Market Research Report 2025

Global Multiple Sclerosis Therapeutics Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1903740

No of Pages : 74

Ask Your Query

Synopsis

Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause the nerves themselves to deteriorate or become permanently damaged.

The global Multiple Sclerosis Therapeutics market was valued at US$ 17030 million in 2023 and is anticipated to reach US$ 19600 million by 2030, witnessing a CAGR of 2.0% during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Multiple Sclerosis Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Sclerosis Therapeutics.

Report Scope

The Multiple Sclerosis Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Sclerosis Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Distribution Channel, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Multiple Sclerosis Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Distribution Channel, and by regions.

Market Segmentation

By Company (Partial List)

  • Novartis
  • Teva Pharmaceuticals
  • Sanofi Genzyme
  • Bayer
  • Pfizer
  • Biogen Idec
  • Merck
  • AbbVie

Segment by Type

  • Beta Interferon
  • Corticosteroids
  • Monoclonal Antibodies
  • Antineoplastic Agents
  • Others

Segment by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Netherlands)
  • Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
  • Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Distribution Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Multiple Sclerosis Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Multiple Sclerosis Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Beta Interferon
1.2.3 Corticosteroids
1.2.4 Monoclonal Antibodies
1.2.5 Antineoplastic Agents
1.2.6 Others
1.3 Market by Distribution Channel
1.3.1 Global Multiple Sclerosis Therapeutics Market Growth by Distribution Channel: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 e-Commerce
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Multiple Sclerosis Therapeutics Market Perspective (2019-2030)
2.2 Multiple Sclerosis Therapeutics Growth Trends by Region
2.2.1 Global Multiple Sclerosis Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Multiple Sclerosis Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Multiple Sclerosis Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Multiple Sclerosis Therapeutics Market Dynamics
2.3.1 Multiple Sclerosis Therapeutics Industry Trends
2.3.2 Multiple Sclerosis Therapeutics Market Drivers
2.3.3 Multiple Sclerosis Therapeutics Market Challenges
2.3.4 Multiple Sclerosis Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Multiple Sclerosis Therapeutics Players by Revenue
3.1.1 Global Top Multiple Sclerosis Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Multiple Sclerosis Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Multiple Sclerosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Multiple Sclerosis Therapeutics Revenue
3.4 Global Multiple Sclerosis Therapeutics Market Concentration Ratio
3.4.1 Global Multiple Sclerosis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Multiple Sclerosis Therapeutics Revenue in 2023
3.5 Multiple Sclerosis Therapeutics Key Players Head office and Area Served
3.6 Key Players Multiple Sclerosis Therapeutics Product Solution and Service
3.7 Date of Enter into Multiple Sclerosis Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Multiple Sclerosis Therapeutics Breakdown Data by Type
4.1 Global Multiple Sclerosis Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Multiple Sclerosis Therapeutics Forecasted Market Size by Type (2025-2030)
5 Multiple Sclerosis Therapeutics Breakdown Data by Distribution Channel
5.1 Global Multiple Sclerosis Therapeutics Historic Market Size by Distribution Channel (2019-2024)
5.2 Global Multiple Sclerosis Therapeutics Forecasted Market Size by Distribution Channel (2025-2030)
6 North America
6.1 North America Multiple Sclerosis Therapeutics Market Size (2019-2030)
6.2 North America Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Multiple Sclerosis Therapeutics Market Size by Country (2019-2024)
6.4 North America Multiple Sclerosis Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Multiple Sclerosis Therapeutics Market Size (2019-2030)
7.2 Europe Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Multiple Sclerosis Therapeutics Market Size by Country (2019-2024)
7.4 Europe Multiple Sclerosis Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Multiple Sclerosis Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Multiple Sclerosis Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Multiple Sclerosis Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Multiple Sclerosis Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Multiple Sclerosis Therapeutics Market Size (2019-2030)
9.2 Latin America Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Multiple Sclerosis Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Multiple Sclerosis Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Multiple Sclerosis Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Multiple Sclerosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Multiple Sclerosis Therapeutics Introduction
11.1.4 Novartis Revenue in Multiple Sclerosis Therapeutics Business (2019-2024)
11.1.5 Novartis Recent Development
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Detail
11.2.2 Teva Pharmaceuticals Business Overview
11.2.3 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Introduction
11.2.4 Teva Pharmaceuticals Revenue in Multiple Sclerosis Therapeutics Business (2019-2024)
11.2.5 Teva Pharmaceuticals Recent Development
11.3 Sanofi Genzyme
11.3.1 Sanofi Genzyme Company Detail
11.3.2 Sanofi Genzyme Business Overview
11.3.3 Sanofi Genzyme Multiple Sclerosis Therapeutics Introduction
11.3.4 Sanofi Genzyme Revenue in Multiple Sclerosis Therapeutics Business (2019-2024)
11.3.5 Sanofi Genzyme Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Multiple Sclerosis Therapeutics Introduction
11.4.4 Bayer Revenue in Multiple Sclerosis Therapeutics Business (2019-2024)
11.4.5 Bayer Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Multiple Sclerosis Therapeutics Introduction
11.5.4 Pfizer Revenue in Multiple Sclerosis Therapeutics Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Biogen Idec
11.6.1 Biogen Idec Company Detail
11.6.2 Biogen Idec Business Overview
11.6.3 Biogen Idec Multiple Sclerosis Therapeutics Introduction
11.6.4 Biogen Idec Revenue in Multiple Sclerosis Therapeutics Business (2019-2024)
11.6.5 Biogen Idec Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Multiple Sclerosis Therapeutics Introduction
11.7.4 Merck Revenue in Multiple Sclerosis Therapeutics Business (2019-2024)
11.7.5 Merck Recent Development
11.8 AbbVie
11.8.1 AbbVie Company Detail
11.8.2 AbbVie Business Overview
11.8.3 AbbVie Multiple Sclerosis Therapeutics Introduction
11.8.4 AbbVie Revenue in Multiple Sclerosis Therapeutics Business (2019-2024)
11.8.5 AbbVie Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock